CClinicalTrials.gg
WithdrawnNCT06822374Updated Nov 10, 2025

Hypertonic Saline in Posterior Spinal Fusion

A Phase 2/3 interventional study of Normosol-R and buffered 2% hypertonic saline in Scoliosis Idiopathic and Scoliosis;Congenital, sponsored by Joseph D. Tobias. Withdrawn at 1 site in United States. Open to participants aged 10 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Joseph D. Tobias · Phase 2/3, Interventional, and Treatment

Why this study was withdrawn
No funding
Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
10 Years to 25 Years
Sex
All
01

Study summary

This is a prospective, randomized study in patients greater than or equal to 10 years of age scheduled for an posterior spinal fusion that requires invasive monitoring of arterial blood pressure. Subjects will be randomized to receive either standard of care Normosol-R or buffered 2% hypertonic saline for intraoperative fluid resuscitation.

The primary objective of this study is to compare intraoperative changes in acid-base status and electrolytes based on the type of fluid administered intraoperatively.

The secondary objective is to compare the volume of fluid required and use of adjunctive volume resuscitation with 5% albumin for intraoperative resuscitation when using standard Normosol-R or a novel buffered 2% saline solution.

02

Conditions studied

  • Scoliosis Idiopathic
  • Scoliosis;Congenital

Keywords

  • intraoperative fluid resuscitation
03

In context

Lead sponsor

Joseph D. Tobias is the lead sponsor of 28 studies on the registry; 4 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients > or = 10 years of age
  • ASA 1-3
  • Undergoing a PSF procedure requiring two peripheral intravenous infusions and an arterial cannula

Exclusion criteria

Exclusion Criteria:

  • Arterial cannula is not indicated for the surgical procedure
  • Two peripheral intravenous cannulas are not required
  • An invasive arterial cannula cannot be placed
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Hypertonic saline

    Buffered 2% saline solution instead of standard of care isotonic fluid for fluid resuscitation during intraoperative care.

    Drug: buffered 2% hypertonic saline

  • Active comparator
    Normosol-R

    Isotonic solution of balanced electrolytes in water for fluid resuscitation during intraoperative care.

    Drug: Normosol-R

Interventions

  • DrugNormosol-R

    Standard of care isotonic fluid.

  • Drugbuffered 2% hypertonic saline

    A solution containing 2% sodium chloride (NaCl) that is "buffered" by the addition of another salt like sodium acetate.

06

What researchers measure

Primary outcomes

  1. pH

    pH level from arterial blood gas.

    Time frame: Every 1-2 hours during the surgery

  2. Base deficit

    Base deficit level from arterial blood gas.

    Time frame: Every 1-2 hours during the surgery

  3. Sodium

    Sodium level from arterial blood gas.

    Time frame: Every 1-2 hours during the surgery

  4. Ionized calcium

    Ionized calcium level from arterial blood gas.

    Time frame: Every 1-2 hours during the surgery

  5. Potassium

    Potassium level from arterial blood gas.

    Time frame: Every 1-2 hours during the surgery

Secondary outcomes

  1. Fluid volume

    Volume of fluid required for intraoperative resuscitation.

    Time frame: Duration of surgery (approx. 4-6 hrs.)

07

Study locations

1 site
  • Nationwide Children's
    Columbus, Ohio 43205, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06822374
Lead sponsor
Joseph D. Tobias
Responsible party
Joseph D. Tobias (Chief, Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital) — Sponsor-investigator
First posted
Feb 12, 2025
Start date
Dec 2025 (estimated)
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion